改良CAG方案联合地西他滨治疗难治急性髓系白血病疗效观察

Efficacy observation of modified CAG regimen combined with Decitabine in the treatment of refractory acute myeloid leukemia

目的:探讨改良CAG方案联合地西他滨治疗难治急性髓系白血病(AML)临床疗效。方法:选取难治性AML患者60例随机分为联合组(改良CAG方案联合地西他滨治疗,30例)和常规组(改良CAG方案治疗,30例),比较两组患者临床疗效及不良反应发生率。结果:联合组患者治疗有效率显著高于常规组(93.33%比70.00%,P<0.05)。两组患者肺部感染、心力衰竭、胃肠不适、肝功能损害、血小板减少、脱发、发热等不良反应发生率比较无统计学意义(P>0.05)。结论:改良CAG方案联合地西他滨治疗难治性AML可有效提高患者临床疗效,并不增加治疗不良反应。

Objective： To investigate the clinical efficacy of modified CAG regimen combined with Decitabine in the treatment of refractory acute myeloid leukemia （AML）. Methods ： 60 case of refractory AML patients were selected and randomly divided them into combined group （modified CAG regimen combined with Decitabine treatment, 30 patients） and conventional group （ modified CAG regimen, 30 patients）. The clinical efficacy and the incidence of adverse reactions were compared between the two groups of patients. Results：The effective rate of treatment in the combined group was significantly higher than that in the conventional group（93.33% vs.70.00%, P〈0.05 ）. There was no significant difference in the incidence of adverse reactions such as pulmonary infection, heart failure, gastrointestinal discomfort, liver function damage, thrombocytopenia, hair loss and fever in the two groups （ P〉0.05 ）. Conclusion ： Improved CAG regimen combined with Decitabine in the treatment of refractory AML can effectively improve the clinical efficacy of patients, not significantly increased the adverse reactions of treatment.